Novavax (NVAX) shares were down sharply Thursday after US Health and Human Services Secretary Robert Kennedy Jr., raised doubts about the effectiveness of the company's Covid-19 vaccine.
Novavax's Nuvaxovid Covid-19 vaccine is currently available under conditional approval and is awaiting full approval from the US Food and Drug Administration, which was expected by April 1, Bloomberg reported.
In a CBS News interview on Wednesday, Kennedy attributed the delay to the vaccine's single-antigen composition, saying such vaccines have "never worked" for respiratory diseases.
"We are actually shifting our priorities to multiple antigen vaccines. And [National Institutes of Health] is already working on a number of those," Kennedy said.
Shares of other Covid-19 vaccine manufacturers including Moderna (MRNA), BioNTech (BNTX), Inovio Pharmaceuticals (INO) and Pfizer (PFE) were also falling after Kennedy's comments.
Novavax didn't immediately respond to a request for comment from MT Newswires.
Price: 5.19, Change: -1.56, Percent Change: -23.05
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.